share_log

$58M Merger: Chain Bridge I Acquires Cannabinoid Medicines Innovator, Eyes Nasdaq Listing

$5800万の合併:Chain Bridge Iがカンナビノイド薬剤のイノベーターを買収、ナスダック上場を目指す

Benzinga ·  07/23 23:06

Chain Bridge I(NASDAQ:CBRG)announced on Monday the acquisition of Phytanix Bio, a pharmaceutical company specializing in the development of therapeutics based on cannabinoid and cannabinoid-like molecules. The transaction,valued at $58 million, also includes the assumption of preferred stock and short-term debt, which will convert to preferred stock upon the deal's closure, slated for the fourth quarter of 2024.

Phytanix Bio's Strategic Acquisition Overview

Phytanix Bio, a company founded by formerGW Pharmaceuticalsleaders,holds exclusive intellectual property that has been central to the creation of FDA-approved cannabinoid-based medicines like Sativex and Epidiolex. With...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする